Market Cap 53.83M
Revenue (ttm) 0.00
Net Income (ttm) -61.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 89,700
Avg Vol 256,856
Day's Range N/A - N/A
Shares Out 35.89M
Stochastic %K 1%
Beta -0.25
Analysts Strong Sell
Price Target $11.92

Latest News on IMRX

Immuneering Corporation Announces Grant of Inducement Award

Mar 21, 2025, 4:30 PM EDT - 12 days ago

Immuneering Corporation Announces Grant of Inducement Award


Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Mar 20, 2025, 7:00 AM EDT - 13 days ago

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer


Why Is Immuneering Stock Trading Higher On Tuesday?

Jan 7, 2025, 9:28 AM EST - 3 months ago

Why Is Immuneering Stock Trading Higher On Tuesday?


Immuneering Launches Pancreatic Cancer Advisory Board

Dec 19, 2024, 8:00 AM EST - 3 months ago

Immuneering Launches Pancreatic Cancer Advisory Board


Immuneering Recognizes Melanoma Awareness Month

May 6, 2024, 4:30 PM EDT - 11 months ago

Immuneering Recognizes Melanoma Awareness Month


Immuneering Appoints Thomas J. Schall, Ph.D.

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Immuneering Appoints Thomas J. Schall, Ph.D.


Immuneering to Present at the Jefferies Healthcare Conference

May 30, 2023, 8:00 AM EDT - 2 years ago

Immuneering to Present at the Jefferies Healthcare Conference


Immuneering Announces $30 Million Underwritten Offering

Apr 18, 2023, 9:24 AM EDT - 2 years ago

Immuneering Announces $30 Million Underwritten Offering


Immuneering Corporation (IMRX) Q4 2022 Earnings Call Transcript

Mar 6, 2023, 10:50 PM EST - 2 years ago

Immuneering Corporation (IMRX) Q4 2022 Earnings Call Transcript